Biora Therapeutics, Inc. (BIOR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022 4:01 PM ESTPresented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients Â
Executed a registered direct capital raise of $9.75 million
Presented preclinical results demonstrating the possibilities for systemic delivery of large molecules using the company's systemic delivery platform
Received key patent for oral delivery of GLP-1 receptor agonist Â
Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) --... More
